Mainz Biomed Secures Funding for Pancreatic Cancer Screening Project

Mainz Biomed N.V., a company specializing in genetic diagnostics, has secured public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB) to advance its pancreatic cancer screening test. This development, announced on June 25, 2025, represents a significant endorsement of Mainz Biomed’s technology. The ISB funding will cover up to 50% of the project costs, accelerating the development of their non-invasive, blood-based test designed for the early detection of pancreatic cancer.

This initiative is part of Mainz Biomed's strategy to enhance cancer diagnostics, aiming to detect pancreatic cancer at a more treatable stage. The project is in the feasibility phase, leveraging real clinical blood samples with Crown Bioscience to assess the performance of mRNA biomarkers and a machine learning-driven algorithm. The effort is part of a broader portfolio expansion across multiple cancer types.